Incyte Provides Top-Line Results from Phase II Proof-of-Concept Trial of Ruxolitinib in Patients wit
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq: INCY) announced top-line results of the Phase II, randomized, double-blind, placebo-controlled RECAP trial of ruxolitinib, its oral JAK1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results